The injectable VK2735 is in two phase 3 studies, and in a maintenance trial dosing every other week kept up to 97% of the weight off, compared with 61% on placebo.
Recap by typeshit. Full story at The Motley Fool.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
The Long Investor notes Hims & Hers stock squeezed between a breakout level and its 200-day average, with earnings due November 9 or possible peptide news as a trigger.
An investor account points followers to its latest weekly recap of $NVO, $LLY and the wider obesity market. Details are in the linked roundup.
Loading…